Interesting news on VXCL! Read the comments!
Wednesday May 13, 9:57 am Eastern Time Company Press Release SOURCE: Vaxcel, Inc.
Vaxcel Announces Second Quarter Results
ATLANTA, May 13 /PRNewswire/ -- Vaxcel, Inc. (OTC Bulletin Board: VXCL - news) today
announced a net loss of $506,048 ($0.05 per share) for the first quarter of 1998 compared to a
net loss of $342,973 ($0.04 per share) for the same period last year.
''In March we acquired the exclusive rights to the Beta-Human Chorionic Gonadotropin (BhCG)
proteins for the use in the treatment and/or prevention of cancer,'' reported Paul J. Wilson,
President and CEO of Vaxcel. ''We are still pursuing licensing and other opportunities for our
injectable, oral, and mucosal technologies.''
Additionally, the Vaxcel board of directors has retained the investment banking firm of
Interstate/Johnson Lane Corporation to introduce Vaxcel and its technologies to the trade with the purpose of concluding a strategic transaction for the benefit of the Vaxcel shareholders. [emphasis added]
biz.yahoo.com |
